Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) EP 1 243 278 B1

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
03.01.2007 Bulletin 2007/01

(51) Int Cl.:
A61K 35/14 (2006.01) *A61K 41/00* (2006.01)

(21) Application number: **02014086.9**

(22) Date of filing: **08.02.1993**

(54) **Use of blood having an increased concentration of nitric oxide for the manufacture of a medicament**

Verwendung von Blut mit erhöhter Stickoxidkonzentration zur Herstellung eines Medikaments

Utilisation du sang comprenant une concentration d'oxyde nitrique augmentée pour la préparation d'un médicament

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

(30) Priority: **07.02.1992 US 832798**
04.09.1992 US 941326

(43) Date of publication of application:
25.09.2002 Bulletin 2002/39

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:
93904180.2 / 0 680 346

(73) Proprietor: **Vasogen Ireland Limited**
Clare (IE)

(72) Inventor: **Bolton, Anthony Ernest**
Derbyshire DE45 1BJ (GB)

(74) Representative: **Walker, Ross Thomson et al**
Forrester & Boehmert,
Pettenkoferstrasse 20-22
80336 München (DE)

(56) References cited:
DE-B- 1 068 428
US-A- 4 831 268
US-A- 4 968 483

- **THOMSEN L L ET AL: "TUMOR-DEPENDENT INCREASED PLASMA NITRATE CONCENTRATIONS AS AN INDICATION OF THE ANTITUMOR EFFECT OF FLAVONE-8-ACETIC ACID AND ANALOGUES IN MICE" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 51, no. 1, 1991, pages 77-81, XP000882939 ISSN: 0008-5472**
- **HARBRECHT B G ET AL: "Nitric oxide synthesis serves to reduce hepatic damage during acute murine endotoxemia." CRITICAL CARE MEDICINE. UNITED STATES NOV 1992, vol. 20, no. 11, November 1992 (1992-11), pages 1568-1574, XP002207857 ISSN: 0090-3493**
- **HISHIKAWA K ET AL: "Effect of systemic L-arginine administration on hemodynamics and nitric oxide release in man." JAPANESE HEART JOURNAL. JAPAN JAN 1992, vol. 33, no. 1, January 1992 (1992-01), pages 41-48, XP002207858 ISSN: 0021-4868**
- **PATENT ABSTRACTS OF JAPAN vol. 008, no. 034 (C-210), 15 February 1984 (1984-02-15) & JP 58 198466 A (TEIJIN KK), 18 November 1983 (1983-11-18)**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 243 278 B1

Printed by Jouve, 75001 PARIS (FR)

Description

[0001] THE PRESENT INVENTION relates to method of increasing the concentration of nitric oxide in blood.

[0002] Platelets are the smallest of the formed elements of the blood. Every cubic millimetre of blood contains about 250 million platelets, as compared with only a few thousand white cells. There are about a trillion platelets in the blood of an average human adult. Platelets are not cells, but are fragments of the giant bone-marrow cells called megakaryocytes. When a megakaryocyte matures, its cytoplasm breaks up, forming several thousand platelets. Platelets lack DNA and have little ability to synthesize proteins. When released into the blood, they circulate and die in about ten days. However, platelets do possess an active metabolism to supply their energy needs.

[0003] Because platelets contain a generous amount of contractile protein (actomyosin), they are prone to contract much as muscles do. This phenomenon explains the shrinkage of a fresh blood clot after it stands for only a few minutes. The shrinkage plays a role in forming a hemostatic plug when a blood vessel is cut. The primary function of platelets is that of forming blood clots. When a wound occurs, platelets are attracted to the site where they activate a substance (thrombin) which starts the clotting process. Thrombin, in addition to converting fibrinogen into fibrin, also makes the platelets sticky. Thus, when exposed to collagen and thrombin, the platelets aggregate to form a plug in the hole of an injured blood vessel.

[0004] Platelets not only tend to stick to one another, but to the walls of blood vessels as well. Because they promote clotting, platelets have a key role in the formation of thrombi. The dangerous consequences of thrombi are evident in many cardiovascular and cerebrovascular disorders.

[0005] The precise function of blood platelets in various human disease states has recently become increasingly understood as advances in biochemistry permit the etiologies of diseases to be better understood.

[0006] For example, many attempts have been made to explain the process of atherogenesis, that is, the creation of plaque which narrows arteries and, of particular concern, the coronary arteries. Recently, there has been increasing interest in the possible role of platelets in atherosclerosis.

[0007] In this regard, it has become recognized that nitric oxide (NO) in the blood inhibits blood clotting by preventing the aggregation of blood platelets. See, e.g., Snyder et al., "Biological Roles of Nitric Oxide," Scientific American, May 1992, pages 68-77, the disclosure of which is incorporated herein by reference.

[0008] As the precise biological role of nitric oxide has been explored, it has become known that nitric oxide serves as an important messenger molecule in the brain and other parts of the body, governing diverse biological functions. In blood vessels, the principal endothelium-derived relaxing factor (EDRF) is nitric oxide, which stimulates vasodilation. Nitric oxide also inhibits platelet aggregation and is partially responsible for the cytotoxic actions of macrophages.

[0009] In the brain, nitric oxide mediates the actions of the excitatory neurotransmitter glutamate in stimulating cyclic GMP concentrations. Immunohistochemical studies have localized nitric oxide synthase (NOS) to particular neuronal populations in the brain and periphery. Inhibitors of nitric oxide synthase block physiological relaxation of the intestine induced by neuronal stimulation, indicating that nitric oxide has the properties of a neurotransmitter. In this regard, nitric oxide appears to be a novel type of neuronal messenger, in that, unlike conventional neurotransmitters, nitric oxide is not stored in synaptic vesicles and does not act on typical receptor proteins of synaptic membranes. One function of nitric oxide may be to protect neurons from ischemic and neurotoxic insults. See, Bredt et al., "Cloned and Expressed Nitric Oxide Synthase Structurally Resembles Cytochrome P-450 Reductase", Nature, Vol. 351, June 1991, pages 714-718.

[0010] DE - A - 1 068 428 discloses a method and a device for the preparation of oxygenated blood.

[0011] Thus, in addition to platelet aggregation associated diseases, a number of other disease states in humans are presently believed to be associated with inadequate nitric oxide levels in the blood. These nitric oxide associated conditions include: high blood pressure, neurological conditions such as depression, tumours, bacterial and fungal infections, and impotence.

[0012] The invention relates to the use of an aliquot of blood for the manufacture of a medicament as defined in claim 1.

[0013] Preferably the ozone gas has a concentration of from about 0.5 µg/ml to about 100 µg/ml in the blood.

[0014] Advantageously the ultraviolet radiation has a wavelength of about 253.7 nm.

[0015] Preferably the blood is maintained at a temperature of from about 0°C to about 56 °C while being contacted with the ozone gas and ultraviolet radiation. The preferred temperature range is 37°C to 43°C, the most preferred temperature being 42.5°C.

[0016] The quantity of blood treated may be from 0.01 ml to 400 ml and is preferably about 10 ml, and the blood is contacted with the ozone gas and ultraviolet radiation preferably for a period of about 3 minutes.

[0017] The blood may be human blood.

[0018] The medicament may be for the treatment of high blood pressure, depression, a tumour, a bacterial infection, a fungal infection, or a viral infection.

[0019] The invention will now be described in greater detail.

[0020] Examples 1 and 2 below show that an inhibition of blood platelet aggregation can only be achieved when the

blood is treated with a combination of ozone gas and ultraviolet radiation (UV). Treatment of blood solely with ozone gas produces minimal inhibition of blood platelet aggregation. Treatment of blood solely with ultraviolet light produces no inhibition of platelet aggregation whatsoever. Moreover, Examples 3 and 4 show that the inhibition of blood platelet aggregation proceeds via a nitric oxide mediated mechanism, and that treatment of blood with ultraviolet light and ozone according to the invention increases nitric oxide concentrations in the blood.

[0021] The combined treatment with ozone gas and ultraviolet light has therefore been unexpectedly found to produce a notable increase in the blood concentration of nitric oxide, which may be useful in treating a variety of disorders that are benefitted by increased blood levels of nitric oxide.

[0022] The ozone gas may be provided by any conventional source known in the art, such as an ozonizer. The ozone gas used in connection with the inventive method has a concentration of ozone of from about 0.5 to about 100 μg/ml. Preferably, the ozone gas has a concentration of from about 5 to about 50 μg/ml. The ozone gas is preferably delivered to the blood by means of a medical oxygen carrier, and is preferably contacted with the blood by any means known in the art, preferably by bubbling the ozone/oxygen mixture through the blood sample.

[0023] The ultraviolet radiation may be provided by any conventional source known in the art, for example by a plurality of low-pressure ultraviolet lamps. The invention preferably utilizes a standard UV-C source of ultraviolet radiation. Preferably employed are low-pressure ultraviolet lamps that generate a line spectrum wherein at least about 90% of the radiation has a wavelength of about 253.7 nm. It is believed that ultraviolet radiation having emission wavelengths corresponding to standard UV-A and UV-B sources would also provide acceptable results.

[0024] The blood to be treated with UV/ozone is preferably heated to a temperature of from about 0 to about 56 °C while being contacted with the ozone gas and ultraviolet radiation. Any suitable source of heat known in the art may be employed to heat the blood, preferably one or more infrared lamps. The blood may be heated to about 37-43 °C, most preferably about 42.5 °C, prior to being contacted with the ozone gas and ultraviolet radiation. Preferably, the temperature of the blood is then maintained at about 42.5 °C during the treatment with UV/ozone.

[0025] Alternatively, the blood sample is heated while being subjected to UV radiation, until the blood reaches a predetermined temperature (preferably about 42.5 °C),at which point bubbling of ozone gas through the blood is commenced. The concurrent UV/ozone treatment is then maintained for a predetermined period of time, preferably about 3 minutes.

[0026] Another alternative method involves subjecting the blood to UV/ozone while heating the blood to a predetermined temperature (preferably about 42.5 °C), then either ending the treatment once the predetermined temperature is reached, or continuing UV/ozone treatment for a further period of time, most preferably about 3 minutes.

[0027] Heating the blood to about 42.5 °C with the infrared lamps preferably employed according to the invention has been found to take from about one minute and fifty seconds to about two minutes and ten seconds.

[0028] It will be understood that the source of blood treated according to the invention may be blood from an outside source, such as a blood donor of compatible blood type, which is treated with UV/ozone and then administered to a patient. Alternately, and preferably, the blood to be treated may be withdrawn from the human patient as an aliquot, treated with UV/ozone, then readministered to the patient from whom the aliquot of blood was taken. All or a portion of the blood removed from the patient may be treated and then readministered to the patient.

[0029] In general, from about 0.01 to about 400 ml of blood may be treated according to the invention. Preferred amounts are in the range of about 0.1 to 200 ml, and more preferably from about 1 to 50 ml of blood. The method most preferably involves treating about 10 ml of blood with ozone gas and ultraviolet radiation, then administering (or readministering) the treated blood to the patient by intramuscular injection

[0030] Other conventional techniques known in the art for administering blood may be employed, such as inter-arterial injection, intravenous injection, subcutaneous injection, and intraperitoneal injection. The administration of small volumes of host blood in this fashion is termed micro-auto-hemotherapy.

[0031] The invention may be used in an embodiment wherein blood is continuously removed from a patient's body and circulated through an apparatus which treats the blood with ozone gas and ultraviolet light as described above, before returning the blood to the patient. This procedure would have particular utility, for example, during the performance of operative procedures, such as coronary bypass surgery.

[0032] The blood is contacted with the ozone gas and ultraviolet radiation for a period of time sufficient to effectively raise the nitric oxide blood concentration in the patient. A treatment period of from about a few seconds to about 60 minutes, preferably from about 0.5 minutes to about 10 minutes, and most preferably about 3 minutes, has been found to provide satisfactory increase in nitric oxide blood levels. The blood is preferably maintained at a temperature of about 42.5 °C during the three minute treatment period.

[0033] The method should be carried out under sterile conditions known to those of ordinary skill in the art. The method of the invention may be carried out using conventional apparatus for ozonating blood and irradiating blood with ultraviolet radiation known to those skilled in the medical art. Preferably, an apparatus similar to that disclosed in U.S. Patent No. 4,968,483 is employed to carry out the method of the invention.

[0034] Those skilled in the art will appreciate that the method of increasing nitric oxide blood concentration provided

by the invention will have therapeutic utility for treating a wide range of disease states which may be benefitted by increasing the levels of nitric oxide in the blood.

[0035] The term "treating" as used herein refers to the alleviation of prevention of a particular disorder. In the case of traumatic conditions such as stroke, preventative treatment is obviously preferred. Also, although the term "human" is used to describe the preferred host, those skilled in the art will appreciate that the methods of the invention would have similar utility with other mammals.

[0036] The following diseases are illustrative of known conditions which are potentially treatable : high blood pressure; neurological conditions such as depression; tumours; bacterial, viral, protozoal and fungal infections; and impotence. This list is merely illustrative; those of ordinary skill in the art will appreciate that other disease states benefitted by increasing the concentration of nitric oxide in the blood may be treated with the inventive technique.

[0037] Peripheral vascular disease is thought to be associated with a reduction of endothelial-derived relaxing factor (EDRF), low levels of which lead to a contraction of the smooth muscle of blood vessels, and hence a reduction in the diameter of the lumen of the vessel and a reduction in blood flow the major naturally occurring EDRF is nitric oxide. In addition, nitric oxide stabilises blood platelets, reducing their aggregation. An increase in EDRF (nitric oxide) levels, therefore, has a double beneficial effect on the circulatory system: it inhibits aggregation of platelets, making the blood more fluid, and it enlarges the diameter of the vessels, improving the flow. The reverse, a reduction in nitric oxide levels, may be present in peripheral vascular disease, and the other conditions described above which may be benefitted by increasing the blood concentration of nitric oxide.

[0038] As illustrated in the examples below, the method is believed to increase nitric oxide levels in the blood, which may explain the mode of action in the inventive treatment of peripheral vascular disease and other conditions associated with blood platelet aggregation and nitric oxide deficiency.

[0039] The following examples are given to illustrate the invention but are not deemed to be limiting thereof.

EXAMPLE 1

Inhibition of Blood Platelet Aggregation

[0040] The following experiment was conducted to study the effects of ozone/ultraviolet light treatment on blood platelet activity.

Experimental Procedure

[0041] Samples (20 ml) of peripheral blood were taken from 10 individuals for 13 separate experiments. Each sample was divided into two aliquots. The first aliquot was treated according to the inventive technique, as follows:

[0042] The 10 ml aliquot was treated in vitro for three minutes with ozone gas (variable ozone concentration of 5-50 µg/ml) and ultraviolet light (253.7 nm), at a temperature of 42.5°C. An apparatus as disclosed in U.S. Patent No. 4,968,483 was utilized to carry out the treatment of the blood sample.

[0043] The second 10 ml aliquot from each sample served as an untreated control.

[0044] Platelets were isolated from the control or treated samples by centrifugation, and their ability to aggregate in response to different concentrations of ADP (a natural platelet stimulator) was measured in an aggregometer. A sample of both ozone-treated and untreated blood was used for quantitation of platelet numbers, using a Coulter counter. In some of the experiments described below, aliquots of the blood were treated with different concentrations of ozone. In other experiments performed, the blood was treated in the presence and absence of UV-light irradiation.

[0045] Platelet aggregation in the ozone-treated blood was expressed as a percentage of aggregation in the same-person untreated control blood.

Results

[0046] As shown in Table 1, the results of the experiments indicate that treatment of blood with ozone and ultraviolet light according to the invention inhibits the aggregation of blood platelets. Furthermore, there is an indication that this inhibition is dose related to the ozone concentration (see Table 2).

The effect of high levels of ozone on ADP-stimulated blood platelets

[0047] High levels of ozone (between 35 and 50 µg/ml) caused a measurable inhibition of ADP-induced platelet aggregation (arbitrarily taken as 33.3% inhibition) in 11 of the 13 experiments (8 of the 10 individuals). Taking all the data on all 10 individuals, the mean inhibition of platelet aggregation was 49.2 +/- 27.8% (mean +/- sd). There was no significant difference between the inhibitory effects on blood taken from males and females (mean inhibition 48.1% and

50.7%, respectively).

[0048] This inhibition appears to relate to the concentration of ADP (aggregation stimulator) over the concentration range of 0.01-0.1mM ADP, with lower inhibition at higher concentrations of platelet agonist. However, this relationship did not hold at higher ADP concentrations (Table 1) and could be spurious, although the level of inhibition at 0.01mM ADP is significantly greater than at 0.1mM ADP (71% vs. 95%, $p < 0.02$).

TABLE 1

[0049] The effect of high levels of ozone on the aggregation of human blood platelets in the presence of varying concentrations of ADP.

Date (Individual)	Concentration of ozone (μg/ml)	Concentration of ADP (mM)	Percent Inhibition of Aggregation	Platelet Count Before Ozone -	After Ozone
21.11.91 (F1)	50	10	100		
27.11.91 (M1)	50	5	83.3		
		10	71.4		
		30	75.0		
2.12.91 (F2)	50	10.	0		
		30	10.0		
		100	27.3		
3.12.91 (M2)	50	0.5	67.1		
		1.	57.1		
		5	50.0		
		30	88.1		
6.12.91 (M3)	50	0.1	0	34	49
		0.1	6.2		
		0.5	4.0		
		0.5	0		
11.12.91 (M4)	50	0.05	67.0	46	93
		0.1	62.4		
		1.0	74.3		
		10.0	50.0		
12.12.91 (M5)	50	0.01	67.0	51	121
		0.1	7.1		
		1.0	35.7		
13.12.91 (F1)	50	0.01	63.4	33	87
		0.05	22.7		
		0.1	30.4		
		0.5	15.4		
		1.0	20.8		
		5.0	20.0		
		10.0	27.6		
9.01.92 (M6)	50	0.01	34.2	34	40
		0.05	31.0		
		0.1	9.8		

(continued)

Date (Individual)	Concentration of ozone (µg/ml)	Concentration of ADP (mM)	Percent Inhibition of Aggregation	Platelet Count Before Ozone -	Platelet Count After Ozone
		0.5	15.4		
		1.0	26.2		
		5.0	31.3		
10.01.92 (F3)	50	0.001	71.4	49	64
		0.005	37.5		
		0.01	69.8		
		0.05	33.8		
		0.1	31.2		
		0.5	10.1		
		1.0	21.8		
13.01.92 (F4)	50	0.005	100	49	52
		0.01	100		
		0.05	95.2		
		0.1	92.9		
		0.5	95.8		
		1.0	91.6		
		5.0	95.8		
		10.0	80.0		
15.01.92 (F1)	40	0.01	90.0	81	66
		0.05	71.4		
		0.1	40.7		
		0.5	87.0		
		1.0	81.8		
		5.0	95.5		
		10.0	85.2		
		50.0	84.0		
		100.0	79.1		
21.01.92 (M2)	35	0.01	67.1	68	79

[0050] The following is a summary of the data set forth in Table 1:

ADP mM	0.01	0.05	0.10	0.50	1.00	5.00	10.0
% inhibition of aggregation	70.8 +/-20.9	53.5 +/-26.1	34.7 +/-28.4	37.6 +/-38.4	50.3 +/-28.7	60.7 +/-35.2	60.7 +/-30.4
N=	6	6	8	7	7	4	4

The effect of high levels of ozone on total whole blood platelet counts:

[0051] As any apparent reduction in platelet aggregation following ozone treatment of whole blood could be caused by a loss of platelets from the blood during treatment, total whole platelet counts were performed on the treated and untreated whole blood samples in 9 experiments on blood from 8 individuals. Overall, the platelet count was 115.5 +\- 59.8% of the untreated level following ozonization (range 82-264%).

[0052] Thus, the total platelet counts before and after ozone/UV treatment do not indicate a major loss of platelets from the blood as a result of ozonization.

The effect of different concentrations of ozone on the inhibition of aggregation of human blood platelets stimulated with ADP:

[0053] Three different concentrations of ozone (5, 25, and 50 μg/ml) were used at a range of ADP concentrations in 4 experiments on 4 different individuals. Bulking the data for different ozone concentrations from each individual and calculating the mean for the data from the 4 experiments indicated that there was some dose response relationship between the concentration of ozone used and the inhibition of platelet aggregation (see Table 2).

[0054] Although overall these differences were not significant, in two of the four individuals there was a significantly greater inhibitory effect of ozone at 50 . μg/ml then at 5 μg/ml (see Table 3).

TABLE 2

[0055] The effect of different concentrations of ozone on inhibition of platelet aggregation in the presence of ADP.

Date (Individual)	Concentration of ozone (μg/ml)	Concentration of ADP (mM)	Percent Inhibition of Aggregation	Platelet Count Before Ozone -	After Ozone
3.12.9 (M2)	15	0.1	27.3		
	25	0.1	100		
	5	0.5	0		
	25	0.5			
	50	0.5	67.1		
	5	1.0	0		
	25	1.0	28.6		
	50	1.0	57.1		
	5	5.0	0		
	25	5.0	25.0		
	50	5.0	50.0		
	5	30.0	50.0		
	25	30.0	62.0		
	50	30.0	88.1		
9.01.92 (M6)	5	0.01	20.1 1	34	43
	25	0.01	28.9		45
	50	0.01	34.2		40
	5	0.05	0		
	25	0.05	5.2		
	50	0.05	31.0		
	5	0.1	9.8		
	25	0.1	1.4		
	50	0.1	9.8		
	5	0.5	0		
	25	0.5	0		
	50	0.5	15.4		
	5	1.0	22.5		

(continued)

Date (Individual)	Concentration of ozone (μg/ml)	Concentration of ADP (mM)	Percent Inhibition of Aggregation	Platelet Count Before Ozone -	After Ozone
	25	1.0	13.7		
	50	1.0	26.2		
	5	5.0	0		
	25	5.0	17.8		
	50	5.0	31.5		
10.01.92 (F3)	5	0.001	57.1	49	73
	25	0.001	85.7		90
	50	0.001	71.4		64
	5	0.005	37.5		
	25	0.005	80.0		
	50	0.005	37.5		
	5	0.01	66.4		
	25	0.01	83.2		
	50	0.01	69.8		
	5	0.05	44.9		
	25	0.05	66.9		
	50	0.05	33.8		
	5	0.1	29.3		
	25	0.1	61.0		
	50	0.1	31.2		
	5	0.5	39.4		
	25	0.5	54.5		
	50	0.5	10.1		
	5	1.0	21.8		
	25	1.0	52.9		
	50	1.0	21.8		
13.01.92 (F4)	5	0.005	100	49	60
	25	0.005	100		85
	50	0.005	100		52
	5	0.01	100		
	25	0.01	87.5		
	50	0.01	100		
	5	0.05	84.8		
	25	0.05	97.1		
	50	0.05	95.2		
	5	0.1	82.9		
	25	0.1	91.4		

(continued)

Date (Individual)	Concentration of ozone (μg/ml)	Concentration of ADP (mM)	Percent Inhibition of Aggregation	Platelet Count Before Ozone - After Ozone
	50	0.1	92.9	
	5	0.5	83.3	
	25	0.5	95.8	
	50	0.5	95.8	
	5	1.0	83.2	
	25	1.0	89.5	
	50	1.0	91.6	
	5	5.0	79.2	
	25	5.0	91.7	
	50	5.0	95.8	
	5	10.0	85.3	
	25	10.0	80.0	
	50	10.0	80.0	

[0056] The following is a summary of the data set forth in Table 2:

Concentration of ozone (μg/ml)	5	25	50
Platelet aggregation (%) (mean +/- sd. n=4)	38.5+/-30.9	56.5+/-29.4	55.9+/-26.4

TABLE 3

[0057] The effect of different concentrations of ozone on inhibition of platelet aggregation in two individuals

Concentration of ozone (μg/ml)	5	25	50
Platelet aggregation M2 (%) Difference from 5 μg/ml	15.5+/-20.2	53.9+/-30.0 ns	65.6+/-14.4 p<0.01
Platelet aggregation M6 (%) Difference from 5 μg/ml	8.7+/-9.6	11.2+/-10.2 ns	24.7+/-9.0 p<0.02

ns=not significant

The effect of UV light on the response of platelets to ozone:

[0058] The effect of ozone on the aggregation of human blood platelets was investigated at different concentrations of ADP, in the presence or absence of UV light. The results, shown in Table 4, indicate that, although there may be some platelet aggregation-inhibitory response to ozone alone, this is nearly always greater in the presence of UV light and the effect of UV light was highly significant ($p<0.001$) in this single experiment. This result was also repeated in a second experiment, using a single concentration of ADP (0.01 mM). The results of this second experiment are set forth in Table 5.

TABLE 4

[0059] The effect of UV light on the inhibition of ADP-induced platelet aggregation by ozone at a concentration of 40 μg/ml. (Experiment date 15.01.92, individual F1)

Concentration ADP (mM)	Inhibition of platelet aggregation (56) +UV	-UV
0.01	90.0	60.0
0.05	71.4	0
0.1	40.7	40.7
0.5	87.0	0
1.0	81.8	0
5.0	95.5	19.4
10.0	85.2	18.5
50.0	84.0	16.0
100.0	79.1	4.2
Mean +/- sd	79.4+/-15.1	17.6+/-19.6 (p<0.001)

TABLE 5

[0060] The effect of UV light on platelet aggregation induced by ADP (0.01 mM) in the presence or absence of ozone. (Experiment date 21.01.92, individual M2)

Percent inhibition of platelet aggregation		
Ozone 35 µg/ml+UV	Ozone 35 µg/ml UV	No ozone. UV alone
83.4%	11.2%	0%

[0061] In summary, the results of Example 1 indicate that the in vitro treatment of an aliquot of blood with ozone gas and ultraviolet light inhibits the aggregation of blood platelets. This platelet inhibition has been found to be dose related to the ozone concentration. Further, platelet inhibition was found to critically depend on the combined treatment of ultraviolet light and ozone gas, as evidenced in Tables 4 and 5. Treatment with ozone gas alone resulted in minimal inhibition of platelet aggregation, while treatment with ultraviolet light alone produced no inhibition of platelet aggregation.

EXAMPLE 2

Measurement of Nitric Oxide

[0062] In order to elucidate the mechanism whereby ozonization/UV light affects the aggregation of platelets in treated blood, the concentration of certain oxidized forms of nitrogen were measured.

[0063] The direct measurement of nitric oxide is difficult to achieve. However, nitric oxide is an intermediate in a metabolic pathway in which arginine is converted to citrulline. Other stable end-products are nitrates and nitrites.

[0064] Accordingly, the nitric oxide content for several samples of blood treated with ultraviolet light and ozone gas according to Example 1 were indirectly determined by measuring the combined nitrate plus nitrite concentrations in the samples before and after treatment with ozone/UV light, after converting nitrate to nitrite.

[0065] The results show that there is a small increase in nitrate plus nitrite concentrations after the illustrated treatment. This increase was consistently found in samples treated with ozone gas/UV light. Thus, nitric oxide levels may be enhanced by the treatment with ozone gas/UV light, and this may be part of the mode of action by which an inhibition of blood platelet aggregation is achieved by the invention. This therapeutic effect would be consistent with the etiology of peripheral vascular disease described above.

Conclusions

[0066] The data of Examples 1 and 2 suggest that the treatment of blood with ozone gas and ultraviolet light according to the invention is actually inducing an inhibition of platelet aggregation for the following reasons:

1. The inhibitory effect is at least partially dependent on the concentration of ADP, ozone being more inhibitory at lower ADP concentrations. This may be interpreted as the higher agonist concentrations partially overcoming the inhibitory effect of ozone by "hyperstimulating" the platelets. This suggests that the inhibition is at least partially

reversible, and is probably not acting by destroying the platelet's ability to aggregate.
2. The inhibitory effect appears to be dose related to ozone concentration, with higher concentrations of ozone resulting in a greater inhibition of platelet aggregation.
3. The inhibitory effect is UV-dependent, suggesting that this is not a non-specific toxic effect caused by the oxidative capacity of the ozone gas.

EXAMPLE 3

[0067] Venous blood (20 ml), taken from 13 healthy non-smoking volunteers, 6 females and 7 males, age 20-50 years, was collected into sodium citrate anticoagulant. None of the volunteers had taken any medication for at least one week prior to the investigation. The blood was divided into two 10 ml aliquots. One aliquot was treated with ozone/UV as described below, the other was an untreated control sample.

Ozone treatment of blood samples

[0068] Blood was treated according to the invention with different concentrations of ozone using a device similar to that described in U.S. Patent No. 4,968,483. Ozone in medical oxygen was bubbled through the blood sample at a rate of 0.3 l/min for a fixed period of about 3 minutes. The blood was heated to a temperature of 42.5 °C and exposed to ultraviolet light at a wavelength of 253.7 nm. The concentration of ozone in the oxygen carrier was variable between about 5 and 50 µg/ml, and was measured using an ozone monitor (Humares, Karlsruhe, Germany).

Platelet aggregation studies

[0069] Platelet aggregation was measured essentially by the end point turbidimetric method of Born.
[0070] Platelet rich plasma (PRP) was prepared by centrifuging 10 ml of blood (either ozone-treated or untreated control blood) at room temperature for 20 minutes at 200 x g. Four ml of PRP was diluted by the addition of 1.0 ml of phosphate-buffered saline.
[0071] Diluted PRP (0.225 ml) was placed in an aggregometer cuvette containing a small magnetic stirrer bar (aggregometer model 1002, ADG Instruments Ltd., Codicote, Herts., U.K.) and equilibrated at 37 °C. After stirring was commenced, 0.025 ml of agonist (either ADP - ADP platelet aggregation reaction or collagen - collagen platelet aggregation reagent; both from Sigma Chemical Co., Poole, Dorset, U.K.) was added to the final concentrations indicated in the results section below. The maximum change in light transmission was measured. Platelet aggregation in the ozone-treated samples was expressed as a percent of the aggregation in the control samples for each individual experimental condition.
[0072] Blood platelet counts were performed on whole blood, using a Coulter counter, provided by the Department of Hematology, Northern General Hospital, Sheffield, U.K.

Results

[0073] Following treatment of whole blood with 35-50 µg/ml of ozone in oxygen at a flow rate of 0.3 l/min for 3 min (total mass of ozone reacted: 31.5-45 mg) with exposure to UV, there was an apparent overall increase in the platelet count, to 1461/57% (mean +/- standard deviation, range 81-202%) of the control value in the 12 individuals investigated. This suggests that, under the conditions used in these experiments, the treatment of whole blood with ozone does not destroy the blood platelets. Furthermore, following visual assessment, no marked hemolysis was observed in the treated blood compared with the control blood samples, indicating that the treatment regime had little effect on erythrocyte integrity.
[0074] Platelets from blood treated with 35-50 µg/ml ozone as above showed a reduction in their ability to aggregate in response to ADP (0.001-100 mmol/l concentrations). The overall inhibition of aggregation was 53.1 +/- 31.1% (mean +/- standard deviation, n=13). The inhibition was variable between individuals, ranging from 2.6% to 100%.
[0075] This inhibitory effect of ozone/UV treatment was dependant on the concentration of ADP, showing a higher level of inhibition of platelet aggregation at low concentrations of ADP (see Table 6). The inhibitory effect at 0.01 mmol/l ADP was significantly greater ($p<0.02$) than at 0.1 mmol/l of this agonist (see Table 6).
[0076] With collagen as an inducer of platelet aggregation, platelets treated with 35-50 µg/ml ozone in oxygen also showed a high level of inhibition of aggregation: 74.2 +/- 43.3% with 1 mg/ml collagen and 76.4 +/- 25.2% with 10 mg/ml collagen (n=5).
[0077] A reduction in the concentration of ozone in the oxygen bubbled through the blood sample resulted in a reduction in the effect of treatment on the inhibition of platelet aggregation. This difference was significant in individual responses to treatment, although the overall mean values of the four individuals investigated were not significantly different (see

Table 7).

TABLE 6

[0078] The effect of different concentrations of the platelet agonist ADP on the inhibition of ADP-induced platelet aggregation by treatment of blood in vitro with ozone at a concentration of 50 μg/ml in oxygen and UV irradiation.

Subject	Conc. ADP (mmol/l)	Percent Inhibition of Platelet Aggregation
Male 1	0.5	67.1
	1.0	57.1
	5.0	50.0
Female 1	0.001	71.4
	0.01	69.8
	0.1	31.2
	1.0	21.8
Female 2	0.01	63.4
	0.1	30.4
	1.0	20.8
Mean	0.01	70.8+/-20.9, n=6
	0.05	53.5+/-26.1, n=6
	0.1	34.7+/-28.4, n=8*

* significantly different from 0.01 mmol/l, p<0.02

TABLE 7

[0079] The effect of different concentrations of ozone on the inhibition of ADP-induced platelet aggregation by treatment of whole blood in vitro with ozone in oxygen and UV irradiation.

	Percent Inhibition of Platelet Aggregation		
Subject	5 μg/ml Ozone	25 ug/ml Ozone	50 μg/ml Ozone
Male 1	15.5	53.9	65.6**
Male 2	8.7	11.2	24.7*
Mean (n=4)	38.5	56.5	55.9
sd	30.9	29.4	26.4

** significant at p<0.01
* significant at p<0.02.

EXAMPLE 4

The Effect of UV/Ozone Treatment of Blood in Vitro on the Plasma Nitric Oxide Concentration

Experimental Outline

[0080] Blood (10ml), anticoagulated with sodium citrate, from 14 normal healthy individuals, was treated with UV/ozone gas as described in Example 3, with oxygen containing ozone at a concentration of 20-50 μg/ml. Control blood from each individual was not treated. After removal of the cellular components of the blood by centrifugation at 15 000 x g for 30 seconds, the plasma was stored at -20 °C.

[0081] Nitric oxide, produced metabolically from L-arginine, is unstable and reacts with oxygen to form nitrate and nitrite. Total nitrate plus nitrite was measured after conversion of nitrate to nitrite using a cadmium catalyst. Nitrite was measured colorimetrically using the Griess reagent by a method based on that published by Green, Wagner, Glogowski, Skipper, Wishnok & Tannenbaum in 1982 (Analytical Biochemistry, Vol. 126, pages 131-138). All treated and control

samples were measured in a single assay run.

Results

[0082] The actual values of nitrite concentration varied widely between individuals, ranging from 0.6 - 27.6 µmol/l. To enable comparisons between individuals, the concentration of nitrite in the ozone-treated sample was expressed as a percent of the concentration in the corresponding untreated control. A summary of the results is as follows:

Individual No.	Percent of Nitrite in Ozonated Sample Compared to Control
1	28.0
2	36.7
3	48.9
4	76.4
5	110.0
6	133.3
7	157.6
8	162.9
9	175.8
10	350.0
11	845.5
12	985.7
13	2075.0
14	3067.0
Arithmetic mean	589.5%

[0083] These values do not form a normal distribution. However, an approximate normal distribution can be attained after logarithmic transformation of the data. Following logarithmic transformation, the level of nitrite in the UV/ozone-treated blood samples is significantly greater than in the untreated samples ($p<001$).

Inhibition Studies

[0084] Nitric oxide inhibits platelet aggregation -- this is one of its physiological activities. It is known that the effect of nitric oxide on platelets can be inhibited by free oxyhemoglobin (Salvemini, Radziszewski, Korbut & Vane, Br. J. Pharmacol., Vol. 101, pages 991-995, 1990). We therefore investigated the effect of oxyhemoglobin on the platelet aggregation inhibitory action of treatment of whole blood with UV/ozone gas.

Experimental Outline

[0085] Platelet rich plasma was prepared from whole blood, either treated with UV/ozone or untreated (control), by centrifugation at 200 x g for 20 minutes at room temperature. Platelet aggregation in response to ADP, collagen or thrombin as stimulators was measured in an aggregometer. Oxyhemoglobin was added to the platelet rich plasma subsequent to ozonization and before measuring platelet aggregation activity. If treatment of blood with UV/ozone to inhibit platelet aggregation is acting via a nitric oxide-mediated mechanism, then the addition of oxyhemoglobin should prevent the inhibition of platelet aggregation caused by UV/ozonization. The results are set forth in Table 8 below.

TABLE 8

		Percent platelet ozone/UV inhibition of aggregation after treatment	
		No Hb	10 µmol/l Hb
Subject	Platelet agonist		
Female a	Thrombin 100 iu	23	4
Female b	Thrombin 100 iu	57	0
	Thrombin 10 iu	97	57
	ADP 1 mmol/l	36	0
			79
Male a	Thrombin 10 iu	80	

(continued)

Subject	Platelet agonist	Percent platelet ozone/UV inhibition of aggregation after treatment	
		No Hb	10 μmol/l Hb
	Collagen 1 mg/ml	95	80
	ADP 1 mmol/l	16	0
	ADP 0.1 mmol/l	26	9

[0086] . Although rather variable, two of the three subjects showed consistent reductions of post-UV/ozone therapy platelet aggregation inhibition in the presence of haemoglobin, and the third subject showed some reduction with 3 of the 4 conditions of aggregation used. The overall means of platelet aggregation were 54% without haemoglobin and 29% in the presence of this inhibitor of nitric oxide activity.

Conclusions

[0087] The above data show that ozonization of blood raises the level of nitrite (the stable metabolite of nitric oxide), and that the inhibition of platelet aggregation caused by ozonization of blood can be reversed by haemoglobin, an inhibitor of nitric oxide activity. Taken together, these data strongly suggest that the treatment of blood with UV/ozone increases the in vivo blood levels of nitric oxide, and inhibits the aggregation of platelets via a nitric oxide mediated mechanism.

[0088] The invention being thus described, it will be obvious that the same may be varied in many ways and all such modifications are intended to be included within the scope of the following claims.

Claims

1. The use of an aliquot of blood, which has been contacted with a nitric oxide concentration-increasing effective amount of ozone gas and ultra-violet radiation for the manufacture of a medicament for the treatment of a disease state associated with inadequate nitric oxide levels in the blood.
2. The use of Claim 1, wherein the ozone gas has a concentration of from about 0.5 μg/ml to about 100 μg/ml in the blood.
3. The use of Claim 2, wherein the ozone gas has a concentration of from about 0.5 μg/ml to about 50 μg/ml
4. The use of any one of Claims 1 to 3, wherein the ultraviolet radiation has a wavelength of about 253.7 nm.
5. The use of any one of the preceding claims, wherein the blood is maintained at a temperature of from about 0°C to about 56 °C while being contacted with the ozone gas and ultraviolet radiation.
6. The use of Claim 5, wherein the blood is maintained at a temperature of from about 37 °C to about 43°C while being contacted with the ozone gas and ultraviolet radiation.
7. The use of Claim 6, wherein the blood is maintained at a temperature of about 42.5 °C while being contacted with the ozone gas and ultraviolet radiation.
8. The use of any one of the preceding claims, wherein the blood treated comprises from about 0.01 ml to about 400 ml.
9. The use of Claim 8, wherein the blood treated comprises about 10 ml of blood.
10. The use of any one of the preceding claims, wherein the blood is contacted with the ozone gas and ultraviolet radiation for a period of about 3 minutes.
11. The use of any one of the preceding claims, wherein the blood is human blood.
12. The use of any one of the preceding claims, wherein the disease state selected from the group consisting of high blood pressure, depression, a tumour, a bacterial infection, platelet aggregation associated diseases and a fungal infection.

Patentansprüche

1. Verwendung eines Blutaliquots, das mit einer Stickoxidkonzentration erhöhenden, effektiven Menge an Ozongas und ultravioletter Strahlung behandelt worden ist, für die Herstellung eines Medikaments für die Behandlung eines Erkrankungszustands, der mit unzureichenden Stickoxidgehalten im Blut verbunden ist.

2. Verwendung nach Anspruch 1, wobei das Ozongas eine Konzentration von etwa 0,5 µg/ml bis etwa 100 µg/ml im Blut aufweist.

3. Verwendung nach Anspruch 2, wobei das Ozongas eine Konzentration von etwa 0,5 µg/ml bis etwa 50 µg/ml aufweist.

4. Verwendung nach einem der Ansprüche 1 bis 3, wobei die ultraviolette Strahlung eine Wellenlänge von etwa 253,7 nm aufweist.

5. Verwendung nach einem der vorangehenden Ansprüche, wobei das Blut bei einer Temperatur von etwa 0°C bis etwa 56°C gehalten wird, während es mit dem Ozongas und der ultravioletten Strahlung kontaktiert wird.

6. Verwendung nach Anspruch 5, wobei das Blut bei einer Temperatur von etwa 37°C bis etwa 43°C gehalten wird, während es mit dem Ozongas und der ultravioletten Strahlung kontaktiert wird.

7. Verwendung nach Anspruch 6, wobei das Blut bei einer Temperatur von etwa 42,5°C gehalten wird, während es mit dem Ozongas und der ultravioletten Strahlung kontaktiert wird.

8. Verwendung nach einem der vorangehenden Ansprüche, wobei das behandelte Blut etwa 0,01 bis etwa 400 ml umfaßt.

9. Verwendung nach Anspruch 8, wobei das behandelte Blut etwa 10 ml Blut umfaßt.

10. Verwendung nach einem der vorangehenden Ansprüche, wobei das Blut mit dem Ozongas und der ultravioletten Strahlung für eine Dauer von etwa 3 Minuten kontaktiert wird.

11. Verwendung nach einem der vorangehenden Ansprüche, wobei das Blut menschliches Blut ist.

12. Verwendung nach einem der vorangehenden Ansprüche, wobei der Erkrankungszustand ausgewählt wird aus der Gruppe bestehend aus hohem Blutdruck, Depression, einem Tumor, einer bakteriellen Infektion, mit Blutplättchenaggregation verbundenen Erkrankungen und einer Pilzinfektion.

Revendications

1. Utilisation d'un échantillon de sang, qui a été en contact avec une quantité efficace d'ozone gazeux augmentant la concentration d'oxyde nitrique et une radiation ultraviolette pour la fabrication d'un médicament destiné au traitement d'une pathologie associée à des taux d'oxyde nitrique inadéquats dans le sang.

2. Utilisation selon la revendication 1, dans laquelle l'ozone gazeux a une concentration d'environ 0,5 µg/ml à environ 100 µg/ml dans le sang.

3. Utilisation selon la revendication 2, dans laquelle l'ozone gazeux a une concentration d'environ 0,5 µg/ml à environ 50 µg/ml dans le sang.

4. Utilisation selon l'une quelconque des revendications 1 à 3, dans laquelle la radiation ultraviolette a une longueur d'onde d'environ 253,7 nm.

5. Utilisation selon l'une quelconque des revendications précédentes, dans laquelle le sang est maintenu à une température d'environ 0 °C à environ 56 °C lorsqu'il est en contact avec l'ozone gazeux et la radiation ultraviolette.

6. Utilisation selon la revendication 5, dans laquelle le sang est maintenu à une température d'environ 37 °C à environ

43 °C lorsqu'il est en contact avec l'ozone gazeux et la radiation ultraviolette.

7. Utilisation selon la revendication 6, dans laquelle le sang est maintenu à une température d'environ 42,5 °C lorsqu'il est en contact avec l'ozone gazeux et la radiation ultraviolette.

8. Utilisation selon l'une quelconque des revendications précédentes, dans laquelle le sang traité comprend d'environ 0,01 ml à environ 400 ml.

9. Utilisation selon la revendication 8, dans laquelle le sang traité comprend environ 10 ml de sang.

10. Utilisation selon l'une quelconque des revendications précédentes, dans laquelle le sang est en contact avec de l'ozone gazeux et une radiation ultraviolette pendant une période d'environ 3 minutes.

11. Utilisation selon l'une quelconque des revendications précédentes, dans laquelle le sang est du sang humain.

12. Utilisation selon l'une quelconque des revendications précédentes, dans laquelle la pathologie est choisie dans le groupe constitué par une hypertension artérielle, une dépression, une tumeur, une infection bactérienne, des maladies associées à une agrégation plaquettaire et une infection fongique.

REGISTER ENTRY FOR EP1243278

European Application No EP02014086.9 filing date 08.02.1993

Priorities claimed:
07.02.1992 in United States of America - doc: 832798
04.09.1992 in United States of America - doc: 941326

Earlier Application Under Art. 76: EP93904180.2 Pubn. No EP0680346 filed on 08.02.1993

Designated States AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

Title USE OF BLOOD HAVING AN INCREASED CONCENTRATION OF NITRIC OXIDE FOR THE MANUFACTURE OF A MEDICAMENT

Applicant/Proprietor
VASOGEN IRELAND LIMITED, Shannon Airport House, Shannon, Co., Clare, Ireland [ADP No. 73330748001]

Inventor
ANTHONY ERNEST BOLTON, 7 Wyebank Grove, Bakeswell, Derbyshire DE45 1BJ, United Kingdom [ADP No. 73330755001]

Classified to
A61K A61M

Address for Service
VASOGEN IRELAND LIMITED, Shannon Airport House, Shannon, Co., Clare, Ireland [ADP No. 73330748001]

EPO Representative
ROSS THOMSON WALKER, Forrester & Boehmert,, Pettenkoferstrasse 20-22, 80336 München, Federal Republic of Germany [ADP No. 72396062001]

Publication No EP1243278 dated 25.09.2002
Publication in English

Examination requested 26.08.2003

Patent Granted with effect from 03.01.2007 (Section 25(1)) with title USE OF BLOOD HAVING AN INCREASED CONCENTRATION OF NITRIC OXIDE FOR THE MANUFACTURE OF A MEDICAMENT

08.12.2006 EPO: Search report published on 26.02.2003
Entry Type 25.11 Staff ID. RD06 Auth ID. EPT

**** END OF REGISTER ENTRY ****

RENEWAL DETAILS

PUBLICATION NUMBER EP1243278

PROPRIETOR(S)

Vasogen Ireland Limited, Shannon Airport House, Shannon, Co., Clare, Ireland

DATE FILED 08.02.1993

DATE GRANTED 03.01.2007

DATE NEXT RENEWAL DUE 03.04.2007

DATE NOT IN FORCE

DATE OF LAST RENEWAL

YEAR OF LAST RENEWAL 00

STATUS PATENT IN FORCE

**** END OF REPORT ****